Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class of drugs for the treatment of retinal diseases.

Pharmaceutical

Allegro Ophthalmics

Vicken Karageozian

Michele Gray

John Park

Melvin Sarayba

Hampar Karageozian

The Scientific Advisors - Retina and Cornea team at Allegro Ophthalmics provides expert guidance on the development and application of integrin inhibition therapies for treating retinal and corneal diseases. They leverage their specialized knowledge to support clinical trials, inform drug development strategies, and ensure the efficacy and safety of new ophthalmic treatments.

Scientific Advisors - Retina and Cornea

About

Team members

Other teams at Allegro Ophthalmics

Leadership Team